A Randomized, Open-Label, 2x2 Crossover Phase 1 Study to Evaluate the Bioequivalence of Single Oral Dose of Lu AA21004 20 mg tablet and 2x Lu AA21004 10 mg tablets in Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 02 May 2018
At a glance
- Drugs Vortioxetine (Primary)
- Indications Anxiety disorders; Major depressive disorder
- Focus Pharmacokinetics
- Sponsors Takeda Pharma
- 26 Apr 2018 Status changed from active, no longer recruiting to completed.
- 26 Mar 2018 Planned End Date changed from 9 Sep 2018 to 5 Apr 2018.
- 26 Mar 2018 Status changed from recruiting to active, no longer recruiting.